The IMA Group (IMA) announced on July 21 the acquisition of Medical Research Network for an undisclosed price.
Medical Research Network is a U.S.-based clinical research site located in New York City, specializing in psychiatry and neurology trials focused on central nervous system (CNS) disorders.
IMA provides government workers with medical, psychological and related evaluations, as well as ancillary services, assists payers with case management and occupational health management solutions and offers clinical research firms access to new advances in pharmacology and biotechnology for research subjects.
Medical Research Network will continue operating under its current name and leadership, with core investigators and staff remaining in place. The acquisition adds IMA’s second research site in New York City and its first East Coast location dedicated to CNS trials.
According to data captured in the LevinPro HC database, this transaction represents the 13th clinical trial acquisition of 2025. There were 27 clinical trial transactions announced in 2024, and 42 announced in 2023.
